Cristcot
Cristcot is a strategic pharmaceutical company focused on gastroenterology, aiming to address significant gaps in disease management with a low competitive landscape. Their lead product is designed to halt acute flares in ulcerative colitis, with successful completion of Phase 3 clinical trials. The company is developing a patented hydrocortisone acetate suppository formulation to treat UC, with a strong IP portfolio extending market exclusivity through late 2036. Their mission is to provide innovative treatments for UC, improving patient quality of life and addressing unmet medical needs.
Industries
Nr. of Employees
small (1-50)
Cristcot
Concord, Massachusetts, United States, North America
Patents
Suppository insertion device, suppository, and method of manufacturing a suppository
US-12337130-B2
View Details
Suppository insertion device, suppository, and method of manufacturing a suppository
US-12337130-B2
View DetailsProducts
Hydrocortisone acetate suppository for ulcerative colitis (rescue therapy)
A suppository dosage form of hydrocortisone acetate developed to halt acute flares in ulcerative colitis with a rapid onset of mucosal healing within 4 weeks; developed for targeted rectal delivery and usability with or without maintenance therapies.
Hydrocortisone acetate suppository for ulcerative colitis (rescue therapy)
A suppository dosage form of hydrocortisone acetate developed to halt acute flares in ulcerative colitis with a rapid onset of mucosal healing within 4 weeks; developed for targeted rectal delivery and usability with or without maintenance therapies.
Services
Management and execution of late-stage clinical trials for an ulcerative colitis rescue therapy, including endpoint design and trial operations.
Development of suppository dosage forms and associated applicator devices for targeted rectal delivery and improved retention.
Development of regulatory plans and patent strategies to secure market exclusivity and manage post-approval market dynamics.
Management and execution of late-stage clinical trials for an ulcerative colitis rescue therapy, including endpoint design and trial operations.
Development of suppository dosage forms and associated applicator devices for targeted rectal delivery and improved retention.
Development of regulatory plans and patent strategies to secure market exclusivity and manage post-approval market dynamics.
Expertise Areas
- Gastroenterology therapeutics development
- Ulcerative colitis rescue therapy development
- Rectal/topical drug delivery
- Formulation development for suppositories
Key Technologies
- Suppository formulation development
- Targeted rectal (anal-rectal) drug delivery
- Rapid-release formulation technologies
- Drug-device combination platforms